A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.11550
Abstract: 11550Background: Topotecan and pazopanib (PAZ) individually have clinical benefit in patients (pts) with sarcomas. PAZ is a multi-tyrosine kinase inhibitor and topotecan affects endothelial cells, ... read more here.
Keywords: pazopanib oral; patients metastatic; topotecan patients; oral topotecan ... See more keywords